GL1X · GenesisL1 explorer

MolNFT v1 · #152615 · protein

Crystal structure of PDE4D complexed with a novel inhibitor

6INM · Camp-specific 3',5'-cyclic phosphodiesterase 4D: “Crystal structure of PDE4D complexed with a novel inhibitor”. X-ray diffraction, 3 ligands (AKU, ZN, MG), 5 pockets (best druggability 0.71). MolNFT v1 #152615 on GenesisL1: 3D…

PDB
6INM
Type
protein
Length
641 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Camp-specific 3',5'-cyclic phosphodiesterase 4D
EC
3.1.4.53
UniProt
Q08499
Ligands
AKU, ZN, MG
Pockets
5 · best druggability 0.71

Structure

x-ray diffraction · 2 distinct chains · 68% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACamp-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53)protein32367% helix, 1% strandQ08499
BCamp-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53)protein31869% helix, 1% strandQ08499

Ligands and binding sites

  • AKU · (1S)-1-[2-(1H-indol-3-yl)ethyl]-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carbaldehyde · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14300.710.8239MG, AKU, EDO
24060.710.8243MG, AKU
31780.550.8028empty
42320.550.7725empty
51300.410.7522empty

Interfaces

1 interface between chains.

  • A–B · 785 Ų buried · 12 hydrogen bonds · protein-protein

Compared structures

  • 6INM · Crystal structure of PDE4D complexed with a novel inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.